Psychiatric morbidity in acromegaly: a cohort study and meta-analysis of the literature
Pooled result · DepressionResult — go to the resultRelative risk 1.9 95% CI 1.2–3.2Authors' conclusion
This study reveals a higher risk of psychiatric disorders in acromegaly, particularly depression and anxiety. Consequently, a need for increased psychiatric awareness in acromegaly is warranted.
Study context
- Population
- Patients with acromegaly or NFPA, similar sex distributions; meta-analysis of studies vs NFPA or healthy controls
- Participants
- 105 vs 211
- Comparison
- Acromegaly vs non-functioning pituitary adenomas
- Acromegalyn = 105
- NFPAn = 211reference
- Outcome
- Risk of psychiatric disorders
Methodological detailsrandom effects model
- Random effects model
Pooled result
Depression
Relative risk
1.9
95% CI 1.2–3.2
P = 0.009
Acromegalyvs NFPA
RR 1.9 (95% CI 1.2–3.2); P = 0.009
As reported in the abstract
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Anxiety | 1.4 (0.5–4.4) | P = 0.53 | |
| Meta-analysis: depression8 studies, 1387 patients | 1.8 (1.3–2.5) | ||
| Meta-analysis: anxiety8 studies, 1387 patients | 1.9 (1.1–3.2) | ||
| 0.20.5125Relative risk (log scale) |
Admissions to psychiatric ward
P = 0.006
Pituitary surgery
P < 0.001
Hormone replacement therapy
P = 0.042
Pituitary adenoma size
P < 0.001
Daily opioid use in acromegaly with psychiatric morbidity
- Higher daily opioid use in acromegaly with psychiatric morbidity, associated with arthropathy diagnosis
- P = 0.009
Original publication
Psychiatric morbidity in acromegaly: a cohort study and meta-analysis of the literature. Pituitary. Published 13 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →